Brogden R N, McTavish D
Adis International Limited, Auckland, New Zealand.
Drugs. 1995 Sep;50(3):495-512. doi: 10.2165/00003495-199550030-00007.
Nifedipine 'gastrointestinal therapeutic system' (GITS) is a recently developed formulation that slowly releases the drug into the intestinal tract over a 24-hour period. When administered once daily, it is of similar efficacy to sustained release formulations of felodipine, verapamil, and diltiazem and at least as effective as standard formulations of lisinopril and enalapril, and long-acting propranolol and atenolol in the treatment of patients with mild to moderate essential hypertension. Substitution of nifedipine GITS for conventional formulations of nifedipine, diltiazem or verapamil, maintained adequate control of anginal symptoms in patients with stable angina pectoris. Nifedipine GITS appears to maintain quality of life and is apparently better tolerated than those formulations of nifedipine which require 2 or 3 times daily administration in both elderly and younger patients. In addition, it has minimal effect on lipid and glucose metabolism and reverses left ventricular hypertrophy, and is thus suitable for treatment of the majority of patients with mild to moderate hypertension or angina pectoris.
硝苯地平“胃肠道治疗系统”(GITS)是一种最近开发的制剂,它能在24小时内将药物缓慢释放到肠道中。每日给药一次时,它在治疗轻度至中度原发性高血压患者方面与非洛地平、维拉帕米和地尔硫䓬的缓释制剂疗效相似,且至少与赖诺普利、依那普利的标准制剂以及长效普萘洛尔和阿替洛尔一样有效。用硝苯地平GITS替代硝苯地平、地尔硫䓬或维拉帕米的传统制剂,可维持稳定型心绞痛患者心绞痛症状的充分控制。硝苯地平GITS似乎能维持生活质量,而且在老年和年轻患者中,其耐受性明显优于那些需要每日给药2或3次的硝苯地平制剂。此外,它对脂质和葡萄糖代谢影响极小,并能逆转左心室肥厚,因此适用于大多数轻度至中度高血压或心绞痛患者的治疗。